Evidence map›Paper›PMID 42533811›Full record

ArticleClinical and molecular hepatology2026

Correspondence to letter to the editor on "Integrative multi-omics profiling identifies infiltrative hepatocellular carcinoma as an immunotherapy-resistant subtype with distinct molecular features".

Won Suk Lee, Seonjeong Woo, Sohyun Hwang, Chan Kim, Hong Jae Chon

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and molecular hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Won Suk Lee *Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.
Seonjeong Woo *Department of Life Science, CHA University, Seongnam, Korea.
Sohyun HwangDepartment of Pathology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea. blissfulwin@cha.ac.kr.
Chan KimMedical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea. chan@cha.ac.kr.
Hong Jae ChonMedical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea. minidoctor@cha.ac.kr.

Funding

BeiGeneBoryungDong-A STIMBDxKorea Health Industry Development InstituteMinistry of Education RS-2019-NR040073Ministry of Health and Welfare RS-2024-00438843Ministry of Science and ICTNational Research Foundation of Korea 2023R1A2C2004339OncocrossRocheSillaJenVirocure
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Atezolizumab plus bevacizumabHepatic microenvironmentHost systemic inflammationImmunotherapy resistanceInfiltrative hepatocellular carcinoma

Identifiers

PMID42533811
PMCPMC13430379

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.